DUBLIN–(BUSINESS WIRE)–The “Orphan Drugs Service Market Report 2025” has been added to ResearchAndMarkets.com’s offering.
The global orphan drugs service market is witnessing unprecedented growth, reflecting the increasing focus on rare diseases, investment in biopharmaceutical research, and enhanced collaborations between healthcare providers and researchers. From $37.05 billion in 2024, the market is projected to soar to $43.4 billion by 2025, with a robust CAGR of 17.1%. Growth drivers include government support and patient advocacy initiatives addressing unmet medical needs.
Forecasts indicate that the market will expand to $80.62 billion by 2029, maintaining a significant CAGR of 16.7%. This expansion will be bolstered by advancements in drug discovery technologies, innovations in cell and gene therapies, AI integration in clinical trials, and increased emphasis on regulatory harmonization. The rise in venture capital funding and the demand for precision medicine further contribute to this growth.
Investments in rare diseases are accelerating the market’s trajectory, motivated by the potential for high returns and regulatory incentives like orphan drug designation and market exclusivity. In April 2024, Global Genes highlighted that rare disease-focused companies raised $7.1 billion in the first quarter, marking a 307% increase from the previous year. These investments enhance R&D, making therapies for neglected conditions feasible and accelerating clinical trials and patient access. For instance, Askbio GmbH secured an orphan drug designation from the European Commission for AB-1003, a novel therapy for limb-girdle muscular dystrophy.
Notable acquisitions like Norgine B.V.’s purchase of Theravia Pharma reflect a strategic effort to bolster offerings in rare diseases and specialty pharmaceuticals, targeting Europe and the Asia-Pacific regions. This reflects the strategic focus of key industry players such as Johnson & Johnson, Roche, Pfizer, and Sanofi on expanding their orphan drug service portfolios.
The U.S. remains a dominant player, but Asia-Pacific is rapidly emerging as the fastest-growing region, expanding its market influence through strategic investments and regulatory enhancements. However, the outlook is tempered by ongoing trade tensions and tariffs affecting pharmaceutical supply lines. Companies are adapting by diversifying supply chains, increasing stocks, and seeking trade exemptions for essential medicines.
The orphan drugs service market encompasses services crucial for facilitating research, development, and distribution of rare disease therapies. These services include clinical trial management, pharmacovigilance, distribution, and comprehensive data management, pivotal in delivering new treatments to underserved patient populations.
As the market evolves, companies are intensifying efforts to achieve regulatory approvals crucial for legal manufacturing and distribution of orphan drugs. This strategy ensures timely availability of treatments, addressing critical gaps in healthcare, particularly for genetic, congenital, oncological, and chronic conditions.
This report provides a comprehensive analysis of the orphan drugs service market, detailing global market size, regional insights, and trends shaping the industry’s future. Despite challenges, the market remains resilient, driven by innovation and commitment to addressing unmet medical needs worldwide.
Report Scope
- Types include Congenital Disease, Genetic Disease, Tumors and Cancer, Chronic, and more.
- Therapeutic areas span Oncology, Metabolic Disorders, and others. Applications cover both Adults and Children.
- Key players such as Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., and many others are featured.
- The report covers major regions including Asia-Pacific, Western and Eastern Europe, North America, South America, Middle East, and Africa, including specific countries like the USA, China, and Germany.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2025 – 2029 |
| Estimated Market Value (USD) in 2025 | $43.4 Billion |
| Forecasted Market Value (USD) by 2029 | $80.62 Billion |
| Compound Annual Growth Rate | 17.0% |
| Regions Covered | Global |
Companies Featured
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- AbbVie Inc.
- Bayer AG
- Sanofi S.A.
- Novartis AG
- AstraZeneca PLC
- The Bristol-Myers Squibb Company
- GSK plc.
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- IQVIA Inc.
- CSL Behring GmbH
- Lonza Group AG
- BioMarin Pharmaceutical Inc.
- Fortrea Holdings Inc.
- Medpace Inc.
- Sarepta Therapeutics
- Caidya Inc.
- Cevidra Inc.
For more information about this report visit https://www.researchandmarkets.com/r/jy5x8v
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
